Onco Wiki / drapeau rouge

CML patient elderly or frail (age ≥75, ECOG ≥2 with multiple comorbidities) where toxicit...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

Origine du drapeau rouge

Logique de déclenchement

{
  "any_of": [
    {
      "comparator": ">=",
      "finding": "age_years",
      "threshold": 75
    },
    {
      "finding": "cml_frail_unfit",
      "value": true
    },
    {
      "all_of": [
        {
          "comparator": ">=",
          "finding": "ecog_performance_status",
          "threshold": 2
        },
        {
          "comparator": ">=",
          "finding": "comorbidities_count",
          "threshold": 2
        }
      ]
    }
  ],
  "type": "composite"
}

Notes

Imatinib generally preferred for elderly / frail patients given: (1) lifetime CV-event risk on nilotinib increases with age; (2) treatment-free remission less of a goal in elderly; (3) cost / generic availability + Ukraine reimbursement. STUB — requires clinical co-lead signoff.

Utilisé par

Algorithmes

• ALGO-CML-1L - ALGO-CML-1L
• ALGO-CML-2L - ALGO-CML-2L

Indication

• IND-CML-1L-2GEN-TKI - IND-CML-1L-2GEN-TKI
• IND-CML-ADVANCED-ALLOHCT - IND-CML-ADVANCED-ALLOHCT